Our approach has clear clinical potential for the treatment of AMD at early stages but requires functional human CD34+ cells, representing the progenitor population that is typically used for bone marrow transplantation [35] and is similar to the mouse ckit+Sca-1+ HSPCs used here and in our other studies [36]. The gene discussed is CD34; the disease is age-related macular degeneration.